The new China ADC corridor: what global pharma should source for in 2026.

For most of the last decade, antibody–drug conjugates originating in Greater China were a curiosity in global pharma business-development conversations — interesting on paper, awkward to underwrite. That has changed. Through the second half of 2025 we ran sourcing mandates that placed Chinese-originated ADC assets at or near the top of the candidate list for three separate global buyers, two of them mid-cap pharma. The change is structural, not cyclical, and it deserves a structural response.

The shift compounds three factors visible in the deal flow we see across the desk. The maturation of Chinese clinical infrastructure has narrowed the trial-quality gap. The global commercial rationale increasingly favors sourcing externally for indications where in-house programs are running long. And the financing reset on the seller side has aligned incentives toward earlier, cleaner partnership conversations.

The result is a more demanding sourcing environment. Buyers can no longer wait for a polished auction process and assume the best programs will still be available. Sellers, meanwhile, are learning that global partners expect cleaner data rooms, sharper territorial logic, and a credible ex-China development path before valuation discussions become serious.

We see the corridor less as a single market theme and more as a repeatable operating question: which Greater China ADC programs are sufficiently differentiated, sufficiently transferable, and sufficiently partnerable to justify global development capital? That question is now live across oncology strategy, BD, clinical development, CMC, and portfolio finance.

/ 01Structural, not cyclical

It is tempting to read the recent run of high-profile transactions as a cycle — assets becoming temporarily fashionable, prices clearing high, then a return to local development. We do not think this is the right reading. The underlying scientific and operational capability has strengthened across three vintages, and the regulatory experience accumulated in the NMPA and parallel FDA tracks is now non-trivial.

Capability has compounded across vintages. Treating the asset class as a cyclical theme rather than a structural source materially under-estimates supply.— Internal sourcing memo · December 2025

For buyers, the implication is that ADC sourcing strategy should now be allocated dedicated capacity within the BD function, not handled as an opportunistic add-on. That is not controversial in 2026; it was in 2022.

Dedicated capacity does not mean a larger list of targets. It means a faster first-pass screen, a more explicit view of what kind of ADC risk the organization can absorb, and a pre-agreed route for escalating assets that clear the first scientific and operational gates. The buyers moving fastest tend to separate target biology, linker-payload questions, clinical translatability, and deal structure early, then recombine those workstreams only when the asset deserves full diligence.

That operating discipline matters because the best China-originated opportunities do not all present with the same shape. Some are clinically advanced but commercially narrow. Some have compelling biology but unresolved global manufacturing questions. Others are strategically important because they give a buyer optionality in a target class where internal programs are not yet competitive.

/ 02What buyers source for

Across the engagements we ran in the last twelve months, three sourcing patterns recur:

1. Indication gap-fill. Late-stage assets that complete a portfolio in an indication where the buyer is underweight or running behind on TPP.
2. Platform extension. Earlier-stage assets that extend a buyer's existing ADC platform, acquired alongside know-how rather than as a stand-alone program.
3. Geographic license-back. Established Chinese assets where the buyer takes ex-China rights and the seller retains greater China commercialization, sometimes with a co-development clause.

Each pattern has a distinct deal architecture. The error we see most often is treating a Pattern 3 conversation with a Pattern 1 term-sheet, and vice versa.

The most attractive assets usually combine two of the three patterns. A late-stage indication gap-fill may also bring platform learning. A geographic license-back may also be the first credible entry point into a target biology the buyer has tracked for years. Those combinations create value, but they also create negotiation complexity: control rights, data ownership, regional study design, and manufacturing responsibility need to be decided early.

/ 03Three diligence questions that have changed

How translatable is the trial population?

The standard-of-care benchmark in a Chinese pivotal is not always the standard in the buyer's primary commercial geographies. Diligence has to read the trial design through the buyer's regulatory and reimbursement lens, not the seller's.

The strongest packages show why the study population should matter outside China, not only why the result is statistically positive. That means mapping prior lines of therapy, biomarker definition, comparator relevance, dose modification, and discontinuation patterns against the launch geographies the buyer actually cares about. When those elements are thin, the headline response rate rarely carries the valuation by itself.

What is the manufacturing readiness for ex-China supply?

Tech transfer is now a deal-determining diligence track, not a post-close concern. The CMC question — capacity, comparability, and supply-chain redundancy — frequently surfaces value or risk at a magnitude that dwarfs other line items in the term-sheet.

For ADCs, CMC diligence is unusually unforgiving because antibody, linker, payload, conjugation, fill-finish, and release testing must hold together as one system. A buyer may accept some clinical uncertainty if the biology is compelling. It is much harder to accept a program where global supply, comparability, or payload sourcing cannot be explained with confidence before signing.

Is the IP estate built for global enforcement?

Patent estates filed primarily for the home jurisdiction may have material gaps in the buyer's commercial geographies. A current freedom-to-operate opinion in the relevant territories is now a baseline diligence deliverable.

The IP review needs to cover more than composition claims. Buyers increasingly ask whether linker-payload know-how is protected, how improvements are captured, whether manufacturing process claims travel, and how prosecution strategy lines up with the territories requested in the license. A narrow estate can still support a deal, but only if the commercial field and control rights are drafted around that reality.

/ 04Deal architectures we now see most often

For Pattern 1, upfront-weighted structures are the norm. The asset is typically late-stage and the buyer is willing to pay for certainty. For Pattern 2, milestone-weighted structures dominate — the underlying value sits in optionality. For Pattern 3, royalty-led structures with a clean territorial split are appropriate, often with co-development obligations and reciprocal information rights.

In practice, the cleanest ADC agreements usually make three choices explicit. First, who controls global development decisions once the program leaves the seller's original territory. Second, who is responsible for manufacturing transition and how failure to execute that transition affects economics. Third, how new indications, combinations, and follow-on molecules are allocated when the first program proves strategically useful.

Buyers should also be careful not to over-index on headline upfronts from comparable deals. ADC transactions often hide value in co-development cost sharing, regional commercial options, platform access, supply economics, and step-in rights. A deal that appears cheaper at signing can become expensive if the buyer has accepted operational obligations without enough control.

/ 05What we expect over the next twelve months

The median quality of inbound deal flow will continue to rise — a supply-side phenomenon driven by domestic Chinese capability, not buyer demand. Terms will compress as buyers compete more directly for top-quartile assets, particularly in Pattern 1. Deal architectures will become more complex, with co-development and joint-steering structures more common than they were two years ago.

We expect four signals to separate serious buyers from passive observers. Serious buyers will maintain a live ADC target map, pre-clear internal positions on China-retained rights, keep CMC and regulatory reviewers close to early screens, and decide in advance which asset profiles justify speed. Teams that begin only after an auction launches will still see opportunities, but they will usually be reacting to someone else's process.

For sellers, the lesson is symmetrical. A stronger global story starts before outreach: data-room discipline, English-language study narratives, manufacturing transfer packages, territorial options, and a sober view of which rights should be retained. The best counterparties will pay for clarity. They discount ambiguity.

/ 06A note on conflicts and confidentiality

We disclose, as a matter of practice, that Vision Lifesciences runs sourcing and diligence mandates on assets in this category for both buyers and sellers. Information barriers separate teams across mandates with potential conflicts. No specific counterparties, asset names, or economics referenced above are identifiable.